The National Agency for Food and Drug Administration and
Control (NAFDAC) has approved Chloroquine production for a clinical trial to
tackle the coronavirus.
Mojisola Adeyeye, the Director-General of NAFDAC made the
announcement on Friday at the NAFDAC headquarters, while stating that the use
of Chloroquine is for clinical trials only in a bid to find treatment for the
coronavirus.
She, however, stated that Choloquine has not been approved
by NAFDAC for the treatment of the coronavirus.
According to the DG, NAFDAC:
“In the case of Chloroquine, it has been demonstrated in the
literature and with clinical research which is still ongoing, that Chloroquine
is superior to the Placebo.
“NAFDAC is not approving Chloroquine as a product that has
can be used for coronavirus because there is no submission to us for
registration but because it is under clinical trials, NAFDAC approves medicines
meant for clinical trials.
“Therefore the medicine is being approved just for the
clinical trials,”
She, therefore, called on experts and researchers that are
interested in doing a clinical trial on Chloroquine to approach approved
outlets, adding that a drug company has been given an approval to produce
chloroquine in batches.
“Right now, we have asked one company to make a batch of
Chloroquine for the purpose of the clinical trial,” Adeyeye added.
Nigerians have also been urged by the NAFDAC DG to stop the
use of chloroquine as an anti-malaria drug.
She stated that:
“Nobody should use chloroquine as anti-malaria because of the resistance
that has been proven to develop in the past after the use of chloroquine in the
population.”
Click to signup for FREE news updates, latest information and hottest gists everyday
Advertise on NigerianEye.com to reach thousands of our daily users
No comments
Post a Comment
Kindly drop a comment below.
(Comments are moderated. Clean comments will be approved immediately)
Advert Enquires - Reach out to us at NigerianEye@gmail.com